{
  "paper_id": "XZJRBPY4",
  "abstract": "The CONSORT-EHEALTH checklist is intended for a thors of randomi ed trials e al ating eb-based and Internet-based applications/inter entions, incl ding mobile inter entions, electronic games (incl m ltipla er games), social media, certain telehealth applications, and other interacti e and/or net orked",
  "md5": "48C38E3412A4F9A647954B60D62A529E",
  "sections": [
    {
      "text": "Is this a full powered effectiveness trial or a pilot feasibility trial"
    },
    {
      "title": "Manuscript tracking number",
      "text": "If hi i a JMIR b i i , ea e ide he a c i ac i g be de \" he \" (The ac i g be ca be f d i he b i i ac edge e e ai , he gi a a h i JMIR. If he a e i a ead b i hed i JMIR, he he ac i g be i he f -digi be a he e d f he DOI, be f C a f he e e f h a e e he ab ac , e.g., e h a e e f a a ed . he a / e/ca e de / h c a -a ed ( e be a d e e e f de ed, f a ). (N e: O e he ab ac ha he a a e e g. If h f a g f he a b d f e , c de add g ) Clea elec i n  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  11/53 bi e a a i a 1 2 3 4 5 e e ia Does your paper address subitem b ii C a d a e e e a ec i f he a c i ab ac (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d\n\nT ea e c i ed f a digi a he a e ic i e e i f i g ce a i c i i g f a a h e a ica i de i e i g c g i i e beha i a he a c e , e--e c achi g, c a i g a d ac i g ca abi i ie . The c i e e i a Ve B ief Ad ice a g he A , Ad i e, Ac de .\n\nb iii Open vs closed web based self assessment vs face to face assessments in the METHODS section of the ABSTRACT\n\nMe i h a ici a e e ec i ed ( i e . ff i e), e.g., f a e acce eb i e f a c i ic a c ed i e e g (c ed e g ia ), a d c a if if hi a a e eb-ba ed ia , he e e e face--face c e (a a f he i e e i f a e e ). C ea a if c e e e e f-a e ed h gh e i ai e (a c i eb-ba ed ia ). N e: I adi i a ff i e ia , a e ia ( e -abe ia ) i a e f c i ica ia i hich b h he e ea che a d a ici a hich ea e i bei g ad i i e ed. T a id c f i , e b i ded b i ded i dica ed he e e f b i di g i ead f e , a e i eb-ba ed ia a efe e acce (i.e. a ici a ca e f-e ). (N e: O e i he ab ac ha he ai a e i e i g. If hi i f a i i i i g f he ai b d f e , c ide addi g i ) Clea elec i n Does your paper address subitem b iii C a d a e e e a ec i f he a c i ab ac (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d \"O c e e e e f-e ed ia h e i e.\"  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  12/53 a a a 1 2 3 4 5 a a a a 1 2 3 4 5 a 1b iv RESULTS section in abstract must contain use data R a a /a a , / a ( . ., a /a , , .), a a / a . (N : O a a a a a . I a a , a ) Clea elec i n Does your paper address subitem 1b iv C a a a a a a ( a a \" \" a a ), a a a a a , a a a / a \"556 a a a ( a =277, =279). T --a a a 530 a a ( =265 a a ; 11 a a a a , a 15 a a a ). B a (a a a 16 a a a a ) 89% (236/265) a a a a . A 4--a , 45% (118) a a a a a 7-a , a 29% (76) \" 1b v CONCLUSIONS DISCUSSION in abstract for negative trials C /D a a a a : D a -a a ( a a ), a a , a a a a a a a a . (N : O a a a a a . I a a , a ) Clea elec i n INTRODUCTION a I INTRODUCTION Sc e f c bac d a d e a a f a a e b e a a a 1 2 3 4 5 e e a Doe o r paper addre bi em b C a d a e e e a ec f he a c ab ac ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d \"The Q Ge d g a he a e c e e a e ea e ach e g g ce a 4-ee da e c a ed e b ef ad ce.\" a i Problem and he pe of em ol ion De c be he b e a d he e f e / ha b ec f he d : e ded a a d-a e e e . c a ed b ade hea h ca e g a ? I e ded f a a c a a e a ? G a f he e e , e.g., be g e c -effec e he e e , e ace c e e he ? (N e: De a ab he e e a e ded Me h d de 5) C ea e ec Doe o r paper addre bi em a i C a d a e e e a ec f he a c ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d \"S g a ead g ca e f e e ab e a d e a e dea h d de. I a a fac f e hea h b e a d fe-h ea e g d ea e \" b a a a 1 2 3 4 5 a b I INTRODUCTION S ec f c b ec e h he e 2a ii Scientific background, rationale What is known about the type of system Sc c bac d, a a : W a ab ( ) a b c d (b d c a c d /d a , a a ), a d , . . a a a a d a c c c d , c a d d d, a ac d [2]. B c c c a a . C ea e ec Does your paper address subitem 2a ii C a d a a c a c ( c d a a \" \" d ca d c a c ), ab a b d add a a , b a a cab / a d \"S a a a ad a a ad a a ac c d a acc b , a a ac a -dbac , ca ab a a , a d c -c \" \"Y , a a c da a a a cac a a c a . \" Does your paper address CONSORT subitem 2b C a d a a c a c ( c d a a \" \" d ca d c a c ), ab a b d add a a , b a a cab / a d \"T d ad a b c . T b c d a a c DTI Q G (QG) b a 7-da a c ab c a 4-da . O b c c d d a a QG, a a c c , a d a , a d a c .\" METHODS 3a Description of trial design (such as parallel, factorial including allocation ratio 3b Important changes to methods after trial commencement (such as eligibility criteria , with reasons Doe o pape add e CONSORT bi em a C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d \"We c d c ed a -a , i g e-b i ded, a a e -g , e-egi e ed a d i ed c ed ia , i h 4-ee , 6-h a d 12-h f -.\" Doe o pape add e CONSORT bi em b C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d \"O J 24, 2019, e ad ed he i a c e e a e i i h he a i f ia i g ce a i .\" \"Thi a cha ged ca e e f-e ed 7-da i e a e ce ab i e ce a 4-ee . Thi deci i a i f ed i -a b a ece De hi d hich f d a ia c ia ce i h he R e S a da d, a e ed b i g ce a i e e \" b e a a a 1 2 3 4 5 e e a a Eligibili cri eria for par icipan s 3b i Bug fixes, Downtimes, Content Changes B f e , D e , C e C a e : e ea e a e f e d a c e . A de c f c a e e d e ef e a c de a c a e ade e e e c a a d e a (e. ., a b f e c a e e f c a c e ) (5-) a d e e ec ed e e a a a e f e ced d de c a aff c a e , e fa e /d e , e c. [2]. Clear selec ion Does your paper address subitem 3b i? C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d N b e , D e C e e a e ec ded ed. Does your paper address CONSORT subitem 4a? C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d \" e e ed a c a e f e ad bee a ea 5 c a e e a da f e a ea , e e a e f f , a d ad c e b e e f c a (5 e e a e f A e P e e 18 e f A d d). T e e c c e a c ded ea E , e a c , COPD, c a c ed ca , a d a e ea c d a d b a a de c e f e e e c a de e ed b e d ea .\" https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  17/53 bi e a all i a 1 2 3 4 5 e e ial bi e a all i a 1 2 3 4 5 e e ial 4a-i) Computer / Internet literacy C e / I e e li e ac i f e a i lici de fac eligibili c i e i -hi h ld be e lici l cla ified. Clea elec i n Does your paper address subitem 4a-i? C a d a e ele a ec i f he a c i (i cl de e i a i a k \"like hi \" i dica e di ec e f a c i ), elab a e hi i e b idi g addi i al i f a i i he , b iefl e lai h he i e i a licable/ ele a f d C e li e ac a eci call e i ed f eligibili he ial. I ead, l h e i h cie bile h e f c i ali (5 h ge e a i highe f A le iPh e e i 18 highe f A d id) e e i cl ded. 4a-ii) Open vs. closed, web-based vs. face-to-face assessments: O e . cl ed, eb-ba ed . face--face a e e : Me i h a ici a e e ec i ed ( li e . ffli e), e.g., f a e acce eb i e f a cli ic, a d cla if if hi a a el ebba ed ial, he e e e face--face c e (a a f he i e e i f a e e ), i.e., ha deg ee g he d ea k he a ici a . I li e-l ial , cla if if a ici a e e a i-a a d he he ha i g l i le ide i ie a ible he he ech ical l gi ical ea e (e.g., c kie , e ail c fi a i , h e call ) e e ed de ec / e e he e. Clea elec i n b e a a a 1 2 3 4 5 e e a b Se ings and loca ions here he da a ere collec ed Doe o r paper addre bi em a ii C a d a e e e a ec f he a c ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d \"Pa c a e e ec ed e f a ca e ac ce ac L d a SMS ca a g . P e a d ea e a ca c e e a d ad e e e c a ed a e e a ed. \" \"Pa c a c e ed a e a e e a e e h e a 4-ee af e he -da e\" a iii Informa ion gi ing d ring recr i men I f a g e d g ec e . S ec f h a c a e e b efed f ec e a d he f ed c e ced e (e.g., b h he f ed c e d c e a a a e d , ee a e X26), a h f a a ha e a effec e e f-e ec , e e ec a a d a a b a e . Clear selec ion Doe o r paper addre bi em a iii C a d a e e e a ec f he a c ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d \"Rec e ad e e e a d d f a g e a c a de c bed he f be g a ca ed e f b e beha a e e add a NRT. N e f a d g a e e a ade he a c a bef e a d a .\" https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  19/53 bi em n a all im an 1 2 3 4 5 e en ial bi em n a all im an 1 2 3 4 5 e en ial Does your paper address CONSORT subitem 4b? * C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d \"Pa ici an c m le ed a e i nnai e nline ia ele h ne\" 4b i Report if outcomes were self assessed through online questionnaires Clea l e if c me e e ( elf-)a e ed h gh nline e i nnai e (a c mm n in eb-ba ed ial )\n\nhe i e."
    },
    {
      "title": "Clea elec i n",
      "text": "Does your paper address subitem 4b i? * google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q 22/53 bi e a all i a 1 2 3 4 5 e e ial bi e a all i a 1 2 3 4 5 e e ial i Q ali a ance me h d P ide i f a i ali a a ce e h d e e acc ac a d ali f i f a i ided [1], if a licable. Clea elec i n D e a e add e bi em i C a d a e ele a ec i f he a c i (i cl de e i a i a k \"like hi \" i dica e di ec e f a c i ), elab a e hi i e b idi g addi i al i f a i i he , b iefl e lai h he i e i a licable/ ele a f d e ec ded En e e licabili b bli hing he ce c de and iding c een h c een ca e ide and iding fl cha f he alg i hm ed E e e licabili b bli hi g he ce c de, a d/ idi g c ee h / c ee -ca e ide , a d/ idi g fl cha f he alg i h ed. Re licabili (i.e., he e ea che h ld i i ci le be able e lica e he d ) i a hall a k f cie ific e i g. Clea elec i n D e a e add e bi em C a d a e ele a ec i f he a c i (i cl de e i a i a k \"like hi \" i dica e di ec e f a c i ), elab a e hi i e b idi g addi i al i f a i i he , b iefl e lai h he i e i a licable/ ele a f d Sc ee h be ided i g e 1.  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  23/53 1 2 3 4 5 1 2 3 4 5 i Digi al pre er a ion D : P URL , ; (I A , . , / / ). A , . Clea elec i n Doe o r paper addre bi em i C ( \" \" ), , / A A :// . . / / / ---/ 1234288038 :// . . / / / = . . 2. & = GB ii Acce A : D , / , ( ) , . I , I [1]. T / / , / ( , ). Clea elec i n b a a a 1 2 3 4 5 a Doe o a e add e bi em ii C a a a c a c ( c a a \" \" ca c a c ), ab a b a a a , b a a cab / a \"A a c a a c acc QG .\" iii Mode of deli e fea e f nc ionali ie com onen of he in e en ion and com a a o and he heo e ical f ame o k D c b , a / c a /c a c a a , a ca a [6] ( c a a [1], b a c a c , a a , c., . ., [7, 8] ). T c a c c ( c c a ) [1], [a ] a a c c a c a a ac a c bac [6]. T a c a c c ca c a a c a c ca a c c ca a c a c [6]. I a c a a a [1], c a c , a a a a , c c , c. [1]. Clea elec i n Doe o a e add e bi em iii C a a a c a c ( c a a \" \" ca c a c ), ab a b a a a , b a a cab / a T a \" Q G (QG) a DTI c a a a ca b c c b a a (CBT).\" C \"VBA a a c b ca . I A , A , Ac c a c b UK .\" https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  25/53 bi em n a all im an 1 2 3 4 5 e en ial bi em n a all im an 1 2 3 4 5 e en ial i De c ibe e pa ame e De c ibe e a ame e (e.g., in ended d e and imal iming f e). Cla if ha in c i n ec mmenda i n e e gi en he e , e.g., ega ding iming, f e enc , hea ine f e, if an , a he in e en i n ed ad libi m. Clea elec i n Doe o pape add e bi em i C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d\n\nPa ici an e e ld e he in e en i n a needed."
    },
    {
      "title": "Cla if he le el of h man in ol emen",
      "text": "Cla if he le el f h man in l emen (ca e ide heal h fe i nal , al echnical a i ance) in he e-in e en i n a c -in e en i n (de ail n mbe and e e i e f fe i nal in l ed, if an , a ell a e f a i ance ffe ed, he iming and f e enc f he , h i i ini ia ed, and he medi m b hich he a i ance i deli e ed . I ma be nece a di ing i h be een he le el f h man in l emen e i ed f he ial, and he le el f h man in l emen e i ed f a ine a lica i n ide f a RCT e ing (di c nde i em 21 gene ali abili ).\n\nClea elec i n b e a a a 1 2 3 4 5 e e a Does our paper address subitem C a d a e e e a ec e a c ( c de e a a \" e \" d ca e d ec e a c ), e ab a e e b d add a a e , b e e a e e a cab e/ e e a d \"A a e QG DTI a c a a a e acce a Q C ac , a ad a ed b e Na a Ce e S a a d T a (NCSCT). T e c ac de e a ed CBT-ba ed a a d a c a e ace a d e.\" i Report an prompts reminders used Re a / e de ed: C a e e e e ( e e , e a , e ca , SMS) e e a ca , a e ed e , e e c e c. I a be ece a d be ee e e e / e de e ed e a , a d e e e / e de a e a ca de a RCT e (d c de e 21 e e a ab ). Clea elec i n Does our paper address subitem i C a d a e e e a ec e a c ( c de e a a \" e \" d ca e d ec e a c ), e ab a e e b d add a a e , b e e a e e a cab e/ e e a d \"QG e ece e ca e e a e de e a e e a .\" 1 2 3 4 5 a Comple el defined pre pecified primar and econdar o come mea re incl ding ho and hen he ere a e ed 5 xii Describe any co interventions incl. training support D -( . / ): C H , -. T [1]. I , RCT ( 21 . Clear elec ion Does your paper address subitem 5 xii? * C ( \" \" ), , / \"\"A P (2 4 16 24 ) 12 , \" Does your paper address CONSORT subitem 6a? * C ( \" \" ), , / \"M 4--.\" \"T -7-4--. S -4 14-, -, -, , , SASEQ WEMWBS, ( ).\" S . https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  28/53 b e a a a 1 2 3 4 5 e e a b e a a a 1 2 3 4 5 e e a 6a i Online questionnaires describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed deployed If c e e e b a ed g e e a e , de c be f e e e a da ed f e e a d a CHERRIES e de c be e e a e e e de g ed/de ed [9]. Clea elec i n Does your paper address subitem 6a i C a d a e e e a ec f a c e C e e a ed. O c e e e a e e e a d a e. 6a ii Describe whether and how use including intensity of use dosage was defined measured monitored De c be e e a d e ( c d g e f e/d age) a def ed/ ea ed/ ed ( g , gf e a a , e c.). U e/ad e c a e a ce c e a d be e ed a e ea a . Clea elec i n Does your paper address subitem 6a ii C a d a e e e a ec f a c e Pa c a e gage e e e a ea ed g -a e c . https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  29/53 b e a a a 1 2 3 4 5 e e a b An change ial c me af e he ial c mmenced i h ea n a H am le i e a de e mined NPT: W e a cab e, de a f e e a d e c e g b ca e de ce e a add e ed 6a iii Describe whether, how, and when qualitative feedback from participants was obtained De c be e e , , a d e a a e feedbac f a c a a b a ed (e.g., g e a , feedbac f , e e , f c g ). Clea elec i n Does your paper address subitem 6a iii C a d a e e e a ec f a c e a cab e , a a e feedbac a ca ed. Does your paper address CONSORT subitem 6b C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d g add a f a e , b ef e a e e a cab e/ e e a f d O J 24, 2019, e ad ed e a c e e a e e a f a g ce a .\" \" f a e e f 7-da e a e ce efe ab e 14-da e a e ce a a f g ea e c a ab e d e . \" ee e d ec . b e a a a 1 2 3 4 5 e e a b When a licable e lana i n f an in e im anal e and ing g ideline a Me h d ed gene a e he and m all ca i n e ence NPT: W e a cab e, ca e de e e a ca ed eac a 7a i Describe whether and how expected attrition was taken into account when calculating the sample size De c be e e a d e ec ed a a a e acc e ca c a e a e e. Clea elec i n Does your paper address subitem 7a i? C a d a e e e a ec f a c e ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d \"A -, a c e a e e a e d be a 10% a e e ea e a d 3% e c . T de ec a d ffe e ce 80% e a d 5% T e I e e eeded a d e 194 a c a e (388 a ). A a 20% d , e a ed ec \u2265500 a c a . \" Does your paper address CONSORT subitem 7b? C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d N a cab e  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  31/53 8b Type of randomisation details of any restriction such as blocking and block size 9 Mechanism used to implement the random allocation sequence such as sequentially numbered containers describing any steps taken to conceal the sequence until interventions were assigned 10 Who generated the random allocation sequence who enrolled participants and who assigned participants to interventions Doe o pape add e CONSORT bi em a\n\nCop and paste rele ant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from our manuscript), or elaborate on this item b pro iding additional information not in the ms, or briefl e plain h the item is not applicable/rele ant for our stud Participants ere randomi ed 1:1 (treatment:control) using a block si e of four"
    },
    {
      "title": "Doe o pape add e CONSORT bi em b",
      "text": "Cop and paste rele ant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from our manuscript), or elaborate on this item b pro iding additional information not in the ms, or briefl e plain h the item is not applicable/rele ant for our stud\n\nParticipants ere randomi ed 1:1 (treatment:control) using a block si e of four"
    },
    {
      "title": "Doe o pape add e CONSORT bi em",
      "text": "Cop and paste rele ant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from our manuscript), or elaborate on this item b pro iding additional information not in the ms, or briefl e plain h the item is not applicable/rele ant for our stud \"Participants ere randomi ed 1:1 (treatment:control) using a block si e of four \" \"Researchers randomi ing participants ere blind to allocation until the had performed the randomi ation.\"\n\nhttps://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  32/53 a If done ho a blinded af e a ignmen o in e en ion fo e am le a ici an ca e o ide ho e a e ing o come and ho NPT: Whe he ad e g c -e e e e b ded g a g e b e a a a 1 2 3 4 5 e e a Does your paper address CONSORT subitem 10? * C a d a e e e a ec f he a c ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d \"Re ea che a d g a c a e e b d a ca he e f ed he a d a .\" Ra d a ca e e ce a ge e a ed b he a a age e e c eba e. Pa c a e e a d a ca ed e he he c ea e e e . 11a i Specify who was blinded, and who wasn t S ec f h a b ded, a d h a . U a , eb-ba ed a b e b d he a c a [1, 3] ( h h d be c ea ac edged), b a be b e b d c e a e , h e d g da a a a h e ad e g c -e e ( f a ). Clea elec ion Does your paper address subitem 11a i? * C a d a e e e a ec f he a c ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d Pa c a e e b ded he ea e a ca . he S d a a g e b ded e e e a de g a e ea che e e a a e f e e a ca . https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  33/53 bi em a all im a 1 2 3 4 5 e e ial b If ele an de c i i n f he imila i f in e en i n ( hi i em i all ele a f eheal h ial a i efe imila i f a laceb ham i e e i a ac i e medica i /i e e i ) a S a i ical me h d ed c m a e g f ima and ec nda c me NPT: Whe a licable, de ail f he he a d h he cl e i g b ca e ide ce e a add e ed 11a ii Discuss e.g., whether participants knew which intervention was the intervention of interest and which one was the comparator I f med c e ced e (4a-ii) ca c ea e bia e a d ce ai e ec a i -di c e.g., he he a ici a k e hich i e e i a he i e e i f i e e a d hich e a he c m a a . Clea elec i n Does your paper address subitem 11a ii C a d a e ele a ec i f m he ma c i (i cl de e i a i ma k \"like hi \" i dica e di ec e f m ma c i ), elab a e hi i em b idi g addi i al i f ma i i he m , b iefl e lai h he i em i a licable/ ele a f d Pa ici a e e a a e f he i e e i f i e e . me i f a digi al i e e i a me i ed, ee me h d ec i f m e de ail. Does your paper address CONSORT subitem 11b C a d a e ele a ec i f m he ma c i (i cl de e i a i ma k \"like hi \" i dica e di ec e f m ma c i ), elab a e hi i em b idi g addi i al i f ma i i he m , b iefl e lai h he i em i a licable/ ele a f d a licable b e a a a 1 2 3 4 5 e e a b Me hod fo addi ional anal e ch a bg o anal e and adj ed anal e Does your paper address CONSORT subitem 12a C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d g add a f a e , b ef e a e e a cab e/ e e a f d We ed c -a ed e f b a c e a d -a e -e f c c e . 12a i Imputation techniques to deal with attrition missing values I a ec e dea a / g a e : N a a c a e e e e /c a a a e ded a d a ca g e ea a . S ec f a c a d d e e a ca d ed f e a e e ea ed e a ca a a (a c e e ca e a a g d c aged, a d e a ec e c a LOCF a a be b e a c [4]). Clea elec ion Does your paper address subitem 12a i C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d g add a f a e , b ef e a e e a cab e/ e e a f d \" e f -a 4-ee e e c de ed a c e g f e a c e a e a 2-ee ab e ce; a a g add a a e af e e da e; a c g g ag ee e e c de ce, edge, a de; a d a g c a ge e f-e cac e a e -be g f ba e e.\"  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  35/53 X2 REB IRB Approval and Ethical Considerations recommended as subheading under Methods not a CONSORT item b e a a a 1 2 3 4 5 e e a Does your paper address CONSORT subitem 12b? * C a d a e e e a ec e a c ( c de e a a \" e \" d ca e d ec e a c ), e ab a e e b d add a a e , b e e a e e a cab e/ e e a d \"We ed c e e e a e e a e ec be a ed a CO de ce e d , ea e a e a a c a a e e de . \" X26 i Comment on ethics committee approval Clear selection Does your paper address subitem X26 i? C a d a e e e a ec e a c ( c de e a a \" e \" d ca e d ec e a c ), e ab a e e b d add a a e , b e e a e e a cab e/ e e a d \"A a a a ed b e Hea a d S c a Ca e Re ea c E c C ee A (HSC REC A; e e e ce 18/NI/0171) a d e ea c c e e Dec a a He .\" https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  36/53 bi e a a i a 1 2 3 4 5 e e ia bi e a a i a 1 2 3 4 5 e e ia ii O line info med con en oced e O i e i f ed c e ced e e.g., if c e a b ai ed ff i e i e (h ? Chec b , e c.?), a d ha i f a i a ided ( ee 4a-ii). See [6] f e i e be i c ded i i f ed c e d c e . Clea elec i n Doe o a e add e bi em X ii C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d \"A c ac ( ia h e i e), a ici a e e ided i h d i f a i a d c e ed a e i ai e de e i e e igibi i . If e igib e, a ici a e e i i ed a e d a i -e ba e i e e i he e e igibi i a ec i ed a d i f ed c e a d ba e i e da a c ec ed.\" X iii Safe and ec i oced e Safe a d ec i ced e , i c . i ac c ide a i , a d a e a e ed ce he i e ih d de ec i f ha (e.g., ed ca i a d ai i g, a ai abi i f a h i e) Clea elec i n  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  37/53 RESULTS 13a For each group the numbers of participants who were randomly assigned received intended treatment and were analysed for the primary outcome NPT: The be f ca e ide ce e e f i g he i e e i i each g a d he be f a ie ea ed b each ca e ide i each ce e 13b For each group losses and exclusions after randomisation together with reasons Doe o a e add e bi em X iii C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d The d a c ide ed i a d ha e e b e ed. Pa ici a e e a ed c ac he d ea ia h e e ai if he e e ie ced a ad e e e e . Doe o a e add e CONSORT bi em a C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d \"556 a ici a e e a d i ed ( ea e =277, c =279). The i e i --ea a a i i c ded 530 a ici a ( =265 i each a ; 11 e c ded f a d i a i bef e ia egi a i , a d 15 f c i a i a ba e i e i i ).\"  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  38/53 bi e a a i a 1 2 3 4 5 e e ia a Da e defining he pe iod of ec i men and follo p Does your paper address CONSORT subitem 13b NOTE Preferably this is shown in a CONSORT flow diagram C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d C diag a h i g e 2 13b i Attrition diagram S g ec e ded: A a i i diag a (e.g., i f a ici a i ggi g i i g he i e e i /c a a i each g ed e i e, i i a a i a c e) he fig e ab e de a i g age/d e/e gage e . Clea elec ion Does your paper address subitem 13b i C a d a e e e a ec i f he a c i ci e he fig e be if a icab e (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d C diag a h i g e 2 Does your paper address CONSORT subitem 1 a C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d \"Pa ici a e e ec i ed be ee Ja a a d N e be 2019\" \" i h 4-ee , 6-h a d 12-h f -\"  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  39/53 bi em n a all im an 1 2 3 4 5 e en ial b Wh he ial ended a ed ea l\n\nA able h ing ba eline dem g a hic and clinical cha ac e i ic f each g NPT: When a licable, a de c i i n f ca e ide (ca e l me, alifica i n, e e i e, e c.) and cen e ( l me) in each g 14a i Indicate if critical secular events fell into the study period Cop and pa e rele an ec ion from he man crip (incl de q o e in q o a ion mark \"like hi \" o indica e direc q o e from o r man crip ), or elabora e on hi i em b pro iding addi ional informa ion no in he m , or briefl e plain h he i em i no applicable/rele an for o r d loca ed in able 1 15 i) Report demographics associated with digital divide issues\n\nIn eheal h rial i i par ic larl impor an o repor demographic a ocia ed i h digi al di ide i e , ch a age, ed ca ion, gender, ocial-economic a , comp er/In erne /eheal h li erac of he par icipan , if kno n."
    },
    {
      "title": "Clea elec ion"
    },
    {
      "title": "Does your paper address subitem 15 i? *",
      "text": "Cop and pa e rele an ec ion from he man crip (incl de q o e in q o a ion mark \"like hi \" o indica e direc q o e from o r man crip ), or elabora e on hi i em b pro iding addi ional informa ion no in he m , or briefl e plain h he i em i no applicable/rele an for o r d loca ed in able 1\n\nb e a a a 1 2 3 4 5 e e a b e a a a 1 2 3 4 5 e e a i Repo m l iple denomina o and p o ide defini ion Re e de a a d de def : Re N (a d effec e ) ac a a ge f d a c a [a d e] e d [1], e.g., N e ed, N c e ed, N ed e a e , N ed e a ee , N a c a ed e e e /c a a a ec f c e-def ed e f e e ( ab e a d e a e be e g ). A a c ea def e e f e e e . Clea elec i n Doe o pape add e bi em i C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d g add a f a e , b ef e a e e a cab e/ e e a f d I f a N e ed, N c e ed, N ed e a e , N ed e a ee a e ca ed e e ec e a d Tab e 1, 2 & 3. A a c a e e a a ed e d a e e e a d ed. ii P ima anal i ho ld be in en o ea P a a a d be e --ea , ec da a a e c d c de c a g e , e a a e ca ea a ge a a d ed a e ( ee 18-). Clea elec i n  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  42/53 a Fo each p ima and econda o come e l fo each g o p and he e ima ed effec i e and i p eci ion ch a confidence in e al bi e a a i a 1 2 3 4 5 e e ia Does your paper address subitem 16 ii? C a d a e e e a ec i f he a c i (i c de e i i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d P i a a a i a ITT. \"We e f ed b h i e i --ea (ITT) a d ec (PP) a a e . ITT i c ded a a ici a a ig ed ea e a d c , e ec i e , a i dica ed i Fig e 1. ITT a a i a ed ha a ici a da a a i i g a a d . PP i c ded he b e f a ici a ha ided a e he e f-e ed c e a ee -4.\" See e h d f i a i f i i g da a. Does your paper address CONSORT subitem 17a? * C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d Thi i h i he e e a d i Tab e 3. 17a i) Presentation of process outcomes such as metrics of use and intensity of use I addi i i a / ec da (c i ica ) c e , he e e a i f ce c e ch a e ic f e a d i e i f e (d e, e e) a d hei e a i a defi i i i c i ica . Thi d e efe e ic f a i i (13-b) ( f e a bi a a iab e), b a e c i e e e ic ch a a e age e i e g h . The e be acc a ied b a ech ica de c i i h a e ic i e a e i i defi ed (e.g., i e af e id e i e) [1] ( e de i e 6a). Clea elec ion 17/09/2020 CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  43/53 17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory Doe o pape add e bi em a i C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d P e e a f e a e e e e ca ed Tab e 2 Doe o pape add e CONSORT bi em b C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d A e f c e e e e ed ab e 3 Doe o pape add e CONSORT bi em C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d We e a ed c e e e ed a a e a . F , c a e e ed e da b e a fa ed ed d ffe e ce be ee ea e a d c ( ea e : 7.9, c : 7.5 c a e e e da ). S a , e a e a e % ed c c a e e e da , b a a b , ed d ffe e ce be ee (48.1% ed c ea e 48.9% c ; = .83) bi e a a i a 1 2 3 4 5 e e ia All impo an ha m o nin ended effec in each g o p (f ecific g ida ce ee CONSORT f ha ) 18 i) Subgroup analysis of comparing only users A bg a a i f c a i g e i c i ehea h ia , b if d e, i be e ed ha hi i a e f-e ec ed a e a d ge a bia ed a e f a a d i ed ia ( ee 16-iii). Clea elec ion Does your paper address subitem 18 i? C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d PP a a i i c d c ed i hi d a d e e ed i Tab e 3. PP c e a e e e ed be he ITT c e i he ab e. Does your paper address CONSORT subitem 19? * C a d a e e e a ec i f he a c i (i c de e i a i a \" i e hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d N i c ded a ha b e ed i d  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  45/53 bi em n a all im an 1 2 3 4 5 e en ial bi em n a all im an 1 2 3 4 5 e en ial i Incl de i ac b eache echnical oblem Incl de i ac b eache , echnical blem . Thi d e n nl incl de h ical ha m a ici an , b al inciden ch a e cei ed eal i ac b eache [1], echnical blem , and he ne ec ed/ nin ended inciden . Unin ended effec al incl de nin ended i i e effec [2]. Clea elec i n Doe o a e add e bi em i C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d N a licable, n i ac b eache echnical blem cc ed d ing he d . ii Incl de ali a i e feedback f om a ici an o ob e a ion f om aff e ea che Incl de ali a i e feedback f m a ici an b e a i n f m aff/ e ea che , if a ailable, n eng h and h c ming f he a lica i n, e eciall if he in nin ended/ ne ec ed effec e . Thi incl de (if a ailable) ea n f h e le did did n e he a lica i n a in ended b he de el e . Clea elec i n Doe o a e add e bi em ii C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d n ne ec ded. 17/09/2020 CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  46/53 DISCUSSION I e e a c e h e ba a c g be ef a d ha a d c de g he e e a e de ce NPT: I , , , 1 2 3 4 5 i Re a e d q e ion and mma i e he an e gge ed b he da a a ing i h p ima o come and p oce o come e R , ( ). C ea e ec Doe o pape e bi em i C ( \" \" ), , / \"I RCT Q G , DTI . T -7-4-VBA.\" \"W DTI, 89% (236/265) 74% (196) 4-.\"  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  47/53 bi e a a i a 1 2 3 4 5 e e ia T ial limi a ion add e ing o ce of po en ial bia imp eci ion and if ele an m l iplici of anal e bi e a a i a 1 2 3 4 5 e e ia ii Highligh nan e ed ne e i n gge f e e ea ch High igh a e ed e e i , gge f e e ea ch. Clea elec ion D e a e add e bi em ii C a d a e e e a ec i f he a c i (i c de e i a i a k \" ike hi \" i dica e di ec e f a c i ), e ab a e hi i e b idi g addi i a i f a i i he , b ief e ai h he i e i a icab e/ e e a f d \"The ke i i a i f hi d i he h f -e i d f 4-eek . I i k ha e a e cc e a ge i ef a e, a d he c e di g d eak he DTI abi i a id ge -e e a e.\" i T ical limi a i n in eheal h ial T ica i i a i i ehea h ia : Pa ici a i ehea h ia a e a e b i ded. Ehea h ia f e k a a i ici f c e , i c ea i g i k f a T e I e . Di c bia e d e -e f he i e e i / abi i i e , bia e h gh i f ed c e ced e , e ec ed e e . Clea elec ion Gene ali abili e e nal alidi applicabili of he ial finding NPT: E e a a d f he a f d g acc d g he e e , c a a , a e , a d ca e de ce e ed he a b e a a a 1 2 3 4 5 e e a Does o r paper address s bi em i C a d a e e e a ec f he a c ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d L a f e f-e , d a e, ac f e e e e b d g a d c e e a e a d c e ed he a a g h he ce e ed ga e he . i Generali abili o o her pop la ions Ge e a ab he a : I a c a , d c ge e a ab a ge e a I e e a , de f a RCT e g, a d ge e a a e a , c d g a cab f he d e f he ga a Clea elec ion Does o r paper address s bi em i C a d a e e e a ec f he a c ( c de e a a \" e h \" d ca e d ec e f a c ), e ab a e h e b d g add a f a he , b ef e a h he e a cab e/ e e a f d Se e a a f he d a e c ded a ac f ge e a ab a g a ha a ge ha he hea h a d ch a c c d a e a ha he a e a ge c ed f h e, ed ca ed a d e ed a c a . b e a a a 1 2 3 4 5 e e a OTHER INFORMATION 23) Registration number and name of trial registry 21 ii Discuss if there were elements in the RCT that would be different in a routine application setting D c f e e e e e e e e RCT a d be d ffe e a e a ca e (e. ., / e de , e a e e , a e e c -e e ) a d a ac e f e e e e e c d a e e, ad , c e f e e e a ed de f a RCT e . Clear selection Does your paper address subitem 21 ii? C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d T e a a d aded f e a a d T e , a d e RCT a ca ed a e a e e f a acce b . H e e a e e c de e a c a e c ded d c a e a e e ea a d c a c c d . Does your paper address CONSORT subitem 23? C a d a e e e a ec f e a c ( c de e a a \" e \" d ca e d ec e f a c ), e ab a e e b d add a f a e , b ef e a e e a cab e/ e e a f d \"T e a a e e ed e ISRCTN da aba e Dece be 18, 2018 ( :// . c .c /ISRCTN65853476)\" 17/09/2020 CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  50/53 24 Where the full trial protocol can be accessed if available 2 Sources of funding and other support such as supply of drugs role of funders X2 Conflicts of Interest not a CONSORT item bi em a all im a 1 2 3 4 5 e e ial Does your paper address CONSORT subitem 24 Ci e a M l imedia A e di , he efe e ce, c a d a e ele a ec i f m he ma c i (i cl de e i a i ma k \"like hi \" i dica e di ec e f m ma c i ), elab a e hi i em b idi g addi i al i f ma i i he m , b iefl e lai h he i em i a licable/ ele a f d T ial c l i f eel a ailable. Does your paper address CONSORT subitem 25 C a d a e ele a ec i f m he ma c i (i cl de e i a i ma k \"like hi \" i dica e di ec e f m ma c i ), elab a e hi i em b idi g addi i al i f ma i i he m , b iefl e lai h he i em i a licable/ ele a f d \"The d a f ded b he c m a ha d ced he Q i Ge i digi al he a e ic i e e i (Digi al The a e ic , I c).\" X2 i State the relation of the study team towards the system being evaluated I addi i he al decla a i f i e e (fi a cial he i e), al a e he ela i f he d eam a d he em bei g e al a ed, i.e., a e if he a h /e al a a e di i c f m ide ical i h he de el e / f he i e e i . Clear selection 17/09/2020 CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form  https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q  51/53 As a result of using this checklist do ou think our manuscript has impro ed Would ou like to become in ol ed in the CONSORT EHEALTH group Thi d i e f e a e bec i g i ed i a ici a i g i a h a d i i g a \"E a a i a d E ab a i \" d c e\n\nC ea e ec i\n\nAn other comments or questions on CONSORT EHEALTH N S b i"
    },
    {
      "text": "eb ba ed com onen o im o an co in e en ion in i le docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?e--e c ach g, c a g a d ac g ca ab e . The c e e a Ve B ef Ad ce a g he A , Ad e, Ac de .\"b ii Level of human involvement in the METHODS section of the ABSTRACT"
    },
    {
      "text": "inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d Pa ici an c m le ed a e i nnai e nline ia ele h ne ing elf-e 4b ii Report how institutional affiliations are displayed Re h in i i nal affilia i n a e di la ed en ial a ici an [ n eheal h media]en i n.(N a e i ed i em de c ibe nl if hi ma bia e l )Clea elec i nThe in e en ion fo each g o p i h fficien de ail o allo eplica ion incl ding ho and hen he e e ac all admini e ed Men ion name c eden ial affilia ion of he de elope pon T e a e c , I c.\"https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?ii De c ibe he hi o de elopmen p oceDe c ibe he hi o /de elo men oce of he a lica ion and e io fo ma i e e al a ion (e.g., foc g o , abili e ing), a he e ill ha e an im ac on ado ion/ e a e and hel i h in e e ing e l .Clea elec i nDoe o pape add e bi em iiCo and a e ele an ec ion f om he man c i (incl de o e in o a ion ma k \"like hi \" o indica e di ec o e f om o man c i ), o elabo a e on hi i em b o iding addi ional info ma ion no in he m , o b iefl e lain h he i em i no a licable/ ele an fo o d \"QG a de elo ed o e man i e a ion incl ding engagemen i h moke , a ien e e en a i e and cien i c ad i o .\" iii Re i ion and pda ing Re i ion and da ing. Clea l men ion he da e and/o e ion n mbe of he a lica ion/in e en ion (and com a a o , if a licable) e al a ed, o de c ibe he he he in e en ion nde en majo change d ing he e al a ion oce , o he he he de elo men and/o con en a f o en d ing he ial. De c ibe d namic com onen ch a ne feed o changing con en hich ma ha e an im ac on he e licabili of he in e en ion (fo ne ec ed e en ee i em 3b). Clea elec i n Doe o pape add e bi em iii Co and a e ele an ec ion f om he man c i (incl de o e in o a ion ma k \"like hi \" o indica e di ec o e f om o man c i ), o elabo a e on hi i em b o iding addi ional info ma ion no in he m , o b iefl e lain h he i em i no a licable/ ele an fo o d no majo change occ ed o he in e en ion d ing he d https://docs."
    },
    {
      "text": "Does your paper address subitem 14a i?C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d n ne ec ded Does your paper address CONSORT subitem 14b? * C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d a ici an denomina o incl ded in each anal i and he he he anal i a b o iginal a igned g o Does your paper address CONSORT subitem 15? *"
    },
    {
      "text": "inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d \"The d a f nded b he c m an ha d ced he Q i Geni digi al he a e ic in e en i n (Digi al The a e ic , Inc). PS i a aid a i ical c n l an . All he a h e ce AM ecei ed a ala f m n e i in Digi al The a e ic , Inc.\"As a result of using this checklist did ou make changes in our manuscript What were the most important changes ou made as a result of using this checklistChangehe me h d and e l ec i n .How much time did ou spend on going through the checklist INCLUDING making changes in our manuscript"
    }
  ],
  "figures": [
    {
      "description": "eb ba ed com onen o im o an co in e en ion in i le docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?e--e c ach g, c a g a d ac g ca ab e . The c e e a Ve B ef Ad ce a g he A , Ad e, Ac de .\"b ii Level of human involvement in the METHODS section of the ABSTRACT"
    },
    {
      "caption": "i",
      "description": "inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d Pa ici an c m le ed a e i nnai e nline ia ele h ne ing elf-e 4b ii Report how institutional affiliations are displayed Re h in i i nal affilia i n a e di la ed en ial a ici an [ n eheal h media]en i n.(N a e i ed i em de c ibe nl if hi ma bia e l )Clea elec i nThe in e en ion fo each g o p i h fficien de ail o allo eplica ion incl ding ho and hen he e e ac all admini e ed Men ion name c eden ial affilia ion of he de elope pon T e a e c , I c.\"https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?ii De c ibe he hi o de elopmen p oceDe c ibe he hi o /de elo men oce of he a lica ion and e io fo ma i e e al a ion (e.g., foc g o , abili e ing), a he e ill ha e an im ac on ado ion/ e a e and hel i h in e e ing e l .Clea elec i nDoe o pape add e bi em iiCo and a e ele an ec ion f om he man c i (incl de o e in o a ion ma k \"like hi \" o indica e di ec o e f om o man c i ), o elabo a e on hi i em b o iding addi ional info ma ion no in he m , o b iefl e lain h he i em i no a licable/ ele an fo o d \"QG a de elo ed o e man i e a ion incl ding engagemen i h moke , a ien e e en a i e and cien i c ad i o .\" iii Re i ion and pda ing Re i ion and da ing. Clea l men ion he da e and/o e ion n mbe of he a lica ion/in e en ion (and com a a o , if a licable) e al a ed, o de c ibe he he he in e en ion nde en majo change d ing he e al a ion oce , o he he he de elo men and/o con en a f o en d ing he ial. De c ibe d namic com onen ch a ne feed o changing con en hich ma ha e an im ac on he e licabili of he in e en ion (fo ne ec ed e en ee i em 3b). Clea elec i n Doe o pape add e bi em iii Co and a e ele an ec ion f om he man c i (incl de o e in o a ion ma k \"like hi \" o indica e di ec o e f om o man c i ), o elabo a e on hi i em b o iding addi ional info ma ion no in he m , o b iefl e lain h he i em i no a licable/ ele an fo o d no majo change occ ed o he in e en ion d ing he d https://docs."
    },
    {
      "description": "Does your paper address subitem 14a i?C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d n ne ec ded Does your paper address CONSORT subitem 14b? * C and a e ele an ec i n f m he man c i (incl de e in a i n ma k \"like hi \" indica e di ec e f m man c i ), elab a e n hi i em b iding addi i nal inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d a ici an denomina o incl ded in each anal i and he he he anal i a b o iginal a igned g o Does your paper address CONSORT subitem 15? *"
    },
    {
      "description": "inf ma i n n in he m , b iefl e lain h he i em i n a licable/ ele an f d \"The d a f nded b he c m an ha d ced he Q i Geni digi al he a e ic in e en i n (Digi al The a e ic , Inc). PS i a aid a i ical c n l an . All he a h e ce AM ecei ed a ala f m n e i in Digi al The a e ic , Inc.\"As a result of using this checklist did ou make changes in our manuscript What were the most important changes ou made as a result of using this checklistChangehe me h d and e l ec i n .How much time did ou spend on going through the checklist INCLUDING making changes in our manuscript"
    }
  ],
  "num_figures": 4,
  "notes": [
    "CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form"
  ],
  "processing_software": {
    "GROBID": "0.8.2"
  }
}
